Indian Pharmas Look To Own Brand Extensions In Combo Market
This article was originally published in PharmAsia News
Indian pharmas are increasingly drawn to applying for brand extensions as they adopt a strategy usually confined to foreign drug makers. The change is due to the popularity of combination drugs in the Indian market, according to a study by ORG IMS. The research firm's report said a third of every new drug launched in India qualify for the term brand extension, accounting for about 18 percent of sales in the country. Analysts see a large increase in brand extensions yet to come as physicians overwhelmed with new products settle for brands they recognize. (Click here for more
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.